**Core Concept**
The underlying principle being tested is the pharmacological effect of **aspirin** on **prostaglandin** and **thromboxane** synthesis. Aspirin acts by inhibiting the enzyme **cyclooxygenase (COX)**, which is crucial for the production of these mediators.

**Why the Correct Answer is Right**
Aspirin, in low doses, selectively inhibits **COX-1**, an isoform of the cyclooxygenase enzyme, leading to a decrease in the production of **thromboxane A2 (TXA2)**, a potent vasoconstrictor that promotes platelet aggregation. This effect is primarily responsible for the antiplatelet activity of aspirin.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because, while aspirin does affect prostaglandin production, its primary effect at low doses is more specific to thromboxane synthesis.
**Option B:** Incorrect as it is not the primary mediator affected by low-dose aspirin.
**Option C:** Incorrect because, although aspirin can influence various pathways, its low-dose effect is most notably on thromboxane A2.
**Option D:** Incorrect as it is not directly related to the primary action of aspirin at low doses.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that the antiplatelet effect of aspirin, through the inhibition of TXA2 production, is the basis for its use in preventing **arterial thrombosis** and **myocardial infarction**.

**Correct Answer:** D. Thromboxane A2